ACADIA Pharmaceuticals Prices Public Offering of Common Stock
November 27 2018 - 9:20PM
Business Wire
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system (CNS) disorders, today announced the pricing of an
underwritten public offering of 16,176,471 shares of its common
stock, offered at a price to the public of $17.00 per share. The
gross proceeds from this offering to ACADIA are expected to be
approximately $275.0 million, before deducting underwriting
discounts and commissions and other estimated offering expenses
payable by ACADIA. ACADIA has granted the underwriters a 30-day
option to purchase up to an aggregate of 2,426,470 additional
shares of common stock. The offering is expected to close on
November 30, 2018, subject to customary closing conditions.
BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs
& Co. LLC are acting as the joint book-running managers for the
offering. Cowen and Company, LLC is acting as lead manager and
Cantor Fitzgerald & Co., JMP Securities LLC and Needham &
Company, LLC are acting as co-managers for the offering.
The shares of common stock described above are being offered by
ACADIA pursuant to a shelf registration statement filed by ACADIA
with the Securities and Exchange Commission (SEC) that became
automatically effective upon filing. A preliminary prospectus
supplement related to the offering was filed with the SEC and is
available on the SEC’s website located at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus related to this offering, when available, may be
obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College
Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus
Department, Email: dg.prospectus_requests@baml.com, or from J.P.
Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866)
803-9204, or by email to: prospectus-eq_fi@jpmchase.com, or from
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, or by telephone at (866) 471-2526,
or by email to: prospectus-ny@nyemail.gs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About ACADIA PharmaceuticalsACADIA is a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system disorders. ACADIA has developed and is
commercializing the first and only medicine approved for the
treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. In addition, ACADIA has ongoing
clinical development efforts in additional areas with significant
unmet need, including dementia-related psychosis, schizophrenia
inadequate response, schizophrenia-negative symptoms, major
depressive disorder, and Rett syndrome.
Forward-Looking StatementsStatements in this press release that
are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to
statements related to the expected proceeds and timing of the
offering of common stock by ACADIA. These statements are only
predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including market risks and
uncertainties and the satisfaction of customary closing conditions
for an offering of securities. For a discussion of these and other
factors, please refer to ACADIA’s annual report on Form 10-K for
the year ended December 31, 2017 as well as ACADIA’s subsequent
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181127005921/en/
Investor Contact:ACADIA Pharmaceuticals Inc.Elena Ridloff,
CFA(858) 558-2871ir@acadia-pharm.com
Media Contact:ACADIA Pharmaceuticals Inc.Maurissa Messier(858)
768-6068media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024